Advertisement
UK markets closed

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • FTSE 250

    20,164.54
    +112.21 (+0.56%)
     

  • AIM

    771.53
    +3.42 (+0.45%)
     

  • GBP/EUR

    1.1652
    -0.0031 (-0.26%)
     

  • GBP/USD

    1.2546
    +0.0013 (+0.11%)
     

  • Bitcoin GBP

    50,758.02
    +1,478.99 (+3.00%)
     

  • CMC Crypto 200

    1,359.39
    +82.41 (+6.45%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • HANG SENG

    18,475.92
    +268.79 (+1.48%)
     

  • DAX

    18,001.60
    +105.10 (+0.59%)
     

  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     
MONEY:

Best savings accounts that offer above inflation rates

Where to find a top-rated deal that works for you

GSK grabs Roche cancer expert to lead pharma pipeline deals

Reuters - UK Focus

LONDON, April 18 (Reuters) - GlaxoSmithKline (Other OTC: GLAXF - news) said on Wednesday it had hired Kevin Sin from Roche's Genentech unit to head worldwide business development for pharmaceuticals research and development.

Sin, who will join GSK in San Francisco in July, has been responsible for oncology deal-making at Genentech since 2010. He will play a pivotal role as the British drugmaker seeks to strengthen its drug pipeline through acquisitions and licensing deals. (Reporting by Ben Hirschler, editing by Louise Heavens)